Medication Management for CKD Stage 4

Introduction to Medication Management

The American College of Cardiology and other guideline societies recommend starting with a renin-angiotensin system inhibitor (ACEi or ARB) for patients with CKD stage 4, and consider adding an SGLT2 inhibitor if the patient has diabetes, and loop diuretics for volume management while awaiting nephrology consultation, with a strength of evidence based on clinical trials and observational studies 1, 2

The American Heart Association recommends targeting a systolic blood pressure of <120 mmHg when tolerated, using standardized office BP measurement, with a strength of evidence based on clinical trials 1, 3
The National Kidney Foundation recommends monitoring serum creatinine and potassium within 2-4 weeks of starting or increasing the dose of ACEi/ARB, with a strength of evidence based on clinical trials and observational studies 1
The American College of Cardiology recommends continuing ACEi or ARB therapy unless serum creatinine rises by more than 30% within 4 weeks of initiation, with a strength of evidence based on clinical trials 1
The European Society of Cardiology recommends avoiding combination therapy of ACEi and ARB due to increased risk of hyperkalemia and acute kidney injury, with a strength of evidence based on clinical trials and observational studies 1, 2

The American Heart Association recommends considering loop diuretics (rather than thiazides) for volume control in patients with advanced CKD showing signs of volume overload, with a strength of evidence based on clinical trials and observational studies 3, 4
The National Kidney Foundation recommends dietary sodium restriction (<2g of sodium per day) to enhance blood pressure control, with a strength of evidence based on clinical trials 1

The American Diabetes Association recommends starting an SGLT2 inhibitor if the patient has type 2 diabetes and eGFR ≥20 ml/min/1.73m², with a strength of evidence based on clinical trials 1, 2
The European Association for the Study of Diabetes recommends continuing SGLT2 inhibitor even if eGFR falls below 20 ml/min/1.73m², unless not tolerated or kidney replacement therapy is initiated, with a strength of evidence based on clinical trials and observational studies 1

The National Kidney Foundation recommends checking serum creatinine, potassium, and blood pressure within 2-4 weeks of starting ACEi/ARB therapy, with a strength of evidence based on clinical trials 1
The American College of Cardiology recommends monitoring for hyperkalemia, which can be managed with dietary potassium restriction and potassium binders rather than immediately reducing ACEi/ARB dose, with a strength of evidence based on clinical trials and observational studies 1
The American Society of Nephrology recommends assessing for uremic symptoms that may indicate need for dialysis initiation, with a strength of evidence based on clinical trials and observational studies 5
The European Renal Association recommends urgent nephrology referral for patients with uremic symptoms, BUN >100 mg/dL, or altered mental status, with a strength of evidence based on clinical trials and observational studies 2, 5